Correction to: Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer

Wanting Shao^{1,2} · Christina Kuhn³ · Doris Mayr⁴ · Nina Ditsch³ · Magdalena Kailuwait¹ · Verena Wolf¹ · Nadia Harbeck¹ · Sven Mahner¹ · Udo Jeschke^{1,3} · Vincent Cavaillès⁵ · Sophie Sixou^{1,6,7}

Published online: 16 July 2021

© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to:

Journal of Cancer Research and Clinical Oncology
<https://doi.org/10.1007/s00432-021-03670-y>

In the original article, the Fig. 2 is published incorrectly. The correct Fig. 2 is given below.

The original article can be found online at <https://doi.org/10.1007/s00432-021-03670-y>.

✉ Udo Jeschke
udo.jeschke@med.uni-muenchen.de;
Udo.Jeschke@uk-augsburg.de

Wanting Shao
schaowt111@126.com

Christina Kuhn
Christina.kuhn@uk-augsburg.de

Doris Mayr
doris.mayr@med.uni-muenchen.de

Nina Ditsch
nina.ditsch@uk-augsburg.de

Magdalena Kailuwait
magdalena.kailuweit@swmbrk.de

Verena Wolf
verena-wolf@gmx.net

Nadia Harbeck
nadia.harbeck@med.uni-muenchen.de

Sven Mahner
sven.mahner@med.uni-muenchen.de

Vincent Cavaillès
vincent.cavaillès@inserm.fr

Sophie Sixou
sophie.sixou@inserm.fr

- 1 Department of Obstetrics and Gynecology, Breast Center, LMU University Hospital, Munich, Germany
- 2 Department of Breast Center, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou 310003, China
- 3 Department of Gynecology and Obstetrics, University Hospital Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany
- 4 Department of Pathology, LMU Munich, Munich, Germany
- 5 IRCM—Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université Montpellier, Parc Euromédecine, 208 rue des Apothicaires, F-34298 Montpellier, France
- 6 Faculté Des Sciences Pharmaceutiques, Université Toulouse III - Paul Sabatier, 31062 Toulouse, France
- 7 Cholesterol Metabolism and Therapeutic Innovations, Cancer Research Center of Toulouse (CRCT), UMR 1037, INSERM, UPS, Université de Toulouse, CNRS, 31037 Toulouse, France

Fig. 2 Kaplan–Meier analyses of patient overall survival (OS) in the whole cohort according to nuclear, cytoplasmic, and total LXR expression. OS Kaplan–Meier curves are presented according to total (A), nuclear (B), and cytoplasmic (C) LXR expression. The optimal

IRS cut-off values for nuclear, cytoplasmic, and total LXR expression were determined as 2.5, 5, and 8.5, respectively. The number of cases for each group is indicated in each panel

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.